<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        0808210909
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2021
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        REYVOW
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        LASMIDITAN
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        50
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Film-coated tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        8
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        229.90
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="LILLY DEL CARIBE, INC." />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            LILLY DEL CARIBE, INC.
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 354]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            SAUDI INTERNATIONAL TRADING COMPANY LTD (SITCO)
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Eli Lilly and Company
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <table cellspacing="0" cellpadding="0" align="left" dir="ltr"><tbody><tr><td style="vertical-align:top"><p>REYVOW is a prescription medicine used for the acute treatment of migraine attacks with or without aura in adults.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; REYVOW is not used as a preventive treatment of migraine.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; It is not known if REYVOW is safe and effective in children.</p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p dir="ltr"><u>Tell your healthcare provider about all of your medical conditions, including if you:</u></p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; have liver problems</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; have high blood pressure</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; have a low heart rate</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; are allergic to lasmiditan</p><p dir="ltr">&nbsp;</p><p dir="ltr"><u>Tell your healthcare provider about all the medicines you take</u><strong>,</strong> including prescription and over-the-counter medicines, vitamins, and herbal supplements. Your healthcare provider will decide if you can take REYVOW with your other medicines.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><u>Especially, tell your healthcare provider if you take:</u></p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; propranolol or other medicines that can lower your heart rate</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; any medicines that can increase your blood pressure</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; any medicines that make you sleepy</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; anti-depressant medicines called:</p><p dir="ltr">&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; - selective serotonin reuptake inhibitors (SSRIs)</p><p dir="ltr">&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; - serotonin norepinephrine reuptake inhibitors (SNRIs)</p><p dir="ltr">&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;- tricyclic anti-depressants (TCAs)</p><p dir="ltr">&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;- monoamine oxidase inhibitors (MAOIs)</p><p dir="ltr">&nbsp;</p><p dir="ltr">Ask your healthcare provider or pharmacist for a list of these medicines if you are not sure.</p><p dir="ltr">Know the medicines you take. Keep a list of them and show it to your healthcare provider or pharmacist when you get a new medicine.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><strong>Other medicines and Reyvow</strong></p><p dir="ltr"><u>Using other medicines, herbal or dietary supplements </u></p><p dir="ltr">You should not take other medicines that make you drowsy while taking REYVOW.</p><p dir="ltr"><strong>&nbsp;</strong></p><p dir="ltr"><strong>Using Reyvow with food and drink </strong></p><p dir="ltr">Lasmiditan may be taken with or without food. You should not drink alcohol while taking REYVOW.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><strong>Pregnancy and breast-feeding</strong></p><p dir="ltr"><u>Tell your healthcare provider about all of your medical conditions, including if you:</u></p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; are pregnant or plan to become pregnant. It is not known if REYVOW will harm your unborn baby.</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; are breastfeeding or plan to breastfeed. It is not known if REYVOW passes into your breastmilk.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><strong>Driving and using machines </strong></p><p dir="ltr"><u>&nbsp;</u></p><p dir="ltr"><u>What is the most important information I should know about REYVOW?</u></p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Do not</strong> drive or operate machinery for at least 8 hours after you take REYVOW, even if you feel well enough.</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>You should not</strong> take REYVOW if you cannot wait at least 8&nbsp;hours between taking REYVOW and driving or operating machinery.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><strong>Drug Abuse and Dependence</strong></p><p dir="ltr">Abuse</p><p dir="ltr">Abuse is the intentional, non-therapeutic use of a drug, even once, for its desirable psychological or physiological effects. In a human abuse potential (HAP) study in recreational poly-drug users (n=58), single oral therapeutic doses (100 and 200&nbsp;mg) and a supratherapeutic dose (400&nbsp;mg) of REYVOW were compared to alprazolam (2&nbsp;mg) (C-IV) and placebo. With all doses of REYVOW, subjects reported statistically significantly higher &ldquo;drug liking&rdquo; scores than placebo, indicating that REYVOW has abuse potential. In comparison to alprazolam, subjects who received REYVOW reported statistically significantly lower &ldquo;drug liking&rdquo; scores. In the HAP study, euphoric mood occurred to a similar extent with REYVOW 200&nbsp;mg, REYVOW 400&nbsp;mg, and alprazolam 2&nbsp;mg (43-49%). A feeling of relaxation was noted in more subjects on alprazolam (22.6%) than with any dose of REYVOW (7-11%).</p><p dir="ltr">Phase 2 and 3 studies indicate that, at therapeutic doses, REYVOW produced adverse events of euphoria and hallucinations to a greater extent than placebo. However these events occur at a low frequency (about 1% of patients).</p><p dir="ltr">Evaluate patients for risk of drug abuse and observe them for signs of lasmiditan misuse or abuse.</p><p dir="ltr">Dependence</p><p dir="ltr">Physical withdrawal was not observed in healthy subjects following abrupt cessation after 7 daily doses of lasmiditan 200&nbsp;mg or 400&nbsp;mg.</p><p dir="ltr">&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p dir="ltr">Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure.</p><p dir="ltr">&nbsp;</p><p dir="ltr">The recommended dose of REYVOW is 50&nbsp;mg, 100&nbsp;mg, or 200&nbsp;mg taken orally, as needed. No more than one dose should be taken in 24&nbsp;hours, and REYVOW should not be taken unless the patient can wait at least 8&nbsp;hours between dosing and driving or operating machinery</p><p dir="ltr">&nbsp;</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Take REYVOW exactly as your healthcare provider tells you to take it.</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Your healthcare provider may change your dose. Do not change your dose without first talking to your healthcare provider.</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Take REYVOW tablets by mouth with or without food.</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Swallow REYVOW tablets whole. Do not split, crush, or chew.</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not take more than one&nbsp;dose in a 24-hour period.</p><p dir="ltr">&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; o&nbsp;&nbsp; If you take REYVOW 50&nbsp;mg, 100&nbsp;mg, or 200&nbsp;mg, and your headache goes away but comes back, you should not take a second dose within 24&nbsp;hours.</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Some people who take too many REYVOW tablets may have worse headaches (medication overuse headache). If your headaches get worse, your healthcare provider may decide to stop your treatment with REYVOW.</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You should write down when you have headaches and when you take REYVOW so you can talk to your healthcare provider about how REYVOW is working for you.</p><p dir="ltr"><strong>If you use more Reyvow than you should </strong></p><p dir="ltr">There is limited clinical trial experience with lasmiditan overdose. In case of an overdose, monitor the patient for any signs or symptoms of adverse reactions and institute supportive treatment as appropriate. There is no known antidote to lasmiditan overdose.</p><p dir="ltr"><strong>If you forget to take Reyvow</strong></p><p dir="ltr">Not applicable.</p><p dir="ltr"><strong>If you stop taking Reyvow</strong></p><p dir="ltr">In a human abuse potential study with recreational drug users, lasmiditan doses of 100 or 200 mg were associated with greater drug liking than placebo. In a separate study, there was no evidence of physical withdrawal in healthy subjects following abrupt cessation of dosing.</p><p dir="ltr">&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p dir="ltr">Like all medicines, Reyvow can cause side effects, although not everybody gets them.</p><p dir="ltr">REYVOW can cause serious side effects including:</p><p dir="ltr"><strong>See &ldquo;What is the most important information I should know about REYVOW?&rdquo;</strong></p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>serotonin syndrome.</strong> Serotonin syndrome is a rare but serious problem that can happen in people using REYVOW, especially if REYVOW is used with anti-depressant medicines called SSRIs or SNRIs. Call your healthcare provider right away if you have any of the following symptoms of serotonin syndrome:</p><p dir="ltr">&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;o mental changes such as seeing things that are not there (hallucinations), agitation, or coma</p><p dir="ltr">&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;o fast heartbeat</p><p dir="ltr">&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;o changes in blood pressure</p><p dir="ltr">&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;o high body temperature</p><p dir="ltr">&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;o tight muscles</p><p dir="ltr">&nbsp; &nbsp; &nbsp; &nbsp;&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; o trouble walking</p><p dir="ltr">&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;o nausea, vomiting, or diarrhea</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>medication overuse headache.</strong> Some people who take medicines like REYVOW for the acute treatment of migraine attacks for 10 or more days each month may have worse headaches (medication overuse headache). If your headaches get worse, your healthcare provider may decide to stop your treatment with REYVOW.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><strong>The most common side effects of REYVOW include</strong></p><p dir="ltr">-&nbsp;dizziness&nbsp; &nbsp; &nbsp;-&nbsp;numbness&nbsp; &nbsp;-&nbsp;tingling</p><p dir="ltr">-&nbsp;sleepiness&nbsp; -&nbsp;feeling tired</p><table border="0" cellspacing="0" cellpadding="0" dir="ltr"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p style="text-align:justify">&nbsp;</p></td></tr></tbody></table><p dir="ltr">Tell your healthcare provider if you have any side effect that bothers you or that does not go away.</p><p dir="ltr">These are not all of the possible side effects of REYVOW. For more information ask your healthcare provider or pharmacist.</p><p dir="ltr">&nbsp;</p><p dir="ltr">If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor, health care provider or pharmacist.</p><p dir="ltr">&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p dir="ltr"><strong>Keep this medicine out of the sight and reach of children.</strong></p><p dir="ltr">Do not use this medicine after the expiry date which is stated on the carton after expiry date &ldquo;EXP.&rdquo;. The expiry date refers to the last day of that month.</p><p dir="ltr">Store below 30&deg;C.</p><p dir="ltr"><strong>&nbsp;</strong></p><p dir="ltr">Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p><p dir="ltr"><strong>&nbsp;</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p dir="ltr">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The activesubstance(s) is <strong>:</strong> lasmiditan hemisuccinate</p><p dir="ltr">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The other&nbsp; excipients are<strong>:</strong> croscarmellose sodium, magnesium stearate, microcrystalline cellulose, pregelatinized starch, sodium lauryl sulfate.</p><p dir="ltr">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Color mixture ingredients: black ferric oxide, polyethylene glycol, polyvinyl alcohol, talc, titanium dioxide. 100&nbsp;mg tablets also contain red ferric oxide.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                REYVOW (lasmiditan) 50 mg tablets are light gray, oval, film coated, tablets with “L-50” debossed on one side and “4312” on the other.
REYVOW (lasmiditan) 100 mg tablets are light purple, oval, film coated, tablets with “L-100” debossed on one side and “4491” on the other.

REYVOW is available in packs containing 4, 8 and 12 tablets.
Not all strengths and  pack sizes may be marketed.


            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p dir="ltr">Marketing Authorization:</p><p dir="ltr">Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana (IN) 46285 USA</p><p dir="ltr">&nbsp;</p><p dir="ltr">Manufacturer:</p><p dir="ltr">The dosage form manufactured at: Lilly del Caribe, Inc., 12.6 KM 65th Infantry Road (PR01), Carolina, Puerto Rico (PR) 00985, USA.</p><p dir="ltr">Packaged and labeled at: Eli Lilly and Company. Lilly Corporate Center, Indianapolis, Indiana 46285, USA.</p><p dir="ltr">&nbsp;</p><p dir="ltr">For any information about this medicinal product, please contact the local representative of the Marketing Authorisation Holder:</p><p dir="ltr">Eli Lilly &amp; Company &ndash; Saudi Arabia</p><p dir="ltr">PO Box 92120</p><p dir="ltr">16th Floor, Building Number 3074,</p><p dir="ltr">Tower B, Olaya Towers</p><p dir="ltr">Prince Mohamed Ibn Abdulaziz Street</p><p dir="ltr">Olaya, Riyadh</p><p dir="ltr">Kingdom of Saudi Arabia</p><p dir="ltr">Direct Line:&nbsp; +966 11 461 7800, +966 11 4617850&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p><p dir="ltr">Fax: +966 11 217 9900</p><p dir="ltr"><strong>&nbsp;</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                	This leaflet was last revised in June 2021.
Version 2
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">رايفو دواء يُستعمل لعلاج نوبات الصداع النصفي الحاد مع أو بدون هالة لدى البالغين.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا يُستعمل رايفو كعلاج وقائيّ للصداع النصفي.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لم يعُرف إذا كان رايفو آمناً وفعّالاً للاستخدام لدى الأطفال.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><u>قبل أن تأخذ رايفو، أعلم طبيبك بكلّ الحالات الطبيّة التي تعاني منها، بما في ذلك</u><u> </u><u>إذا كنت:</u></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تعاني من مشاكل في الكبد</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تعاني من ضغط دم مرتفع</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تعاني من انخفاض في معدّل ضربات القلب</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تعاني من حساسية لمادّة لاسميديتان</p><p dir="RTL">أعلم طبيبك بكلّ الأدوية التي تأخذها، بما فيها الأدوية التي تُصرف بوصفة طبيّة والأدوية التي تحصل عليها بدون وصفة طبيّة والفيتامينات والمكمّلات العشبيّة. سوف يقرّر طبيبك ما إذا كان يمكنك أخذ رايفو مع أدوية أخرى.</p><p dir="RTL">أعلم طبيبك خاصّةً إذا كنت تأخذ:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بروبرانولول أو أدوية أخرى يمكن أن تخفّض معدّل ضربات القلب لديك</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أيّ أدوية يمكن أن ترفع ضغط الدم لديك</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أيّ أدوية تجعلك تشعر بالنعاس</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أدوية مضادة للاكتئاب تُسمّى:</p><p dir="RTL">&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; - المثبّطات الانتقائيّة لإعادة قبط السيروتونين (SSRIs)</p><p dir="RTL">&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; - مثبّطات إعادة قبط السيروتونين النوريبينفرين (SNRIs)</p><p dir="RTL">&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;- مضادات الاكتئاب الثلاثيّة الحلقات (TCAs)</p><p dir="RTL">&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; - مثبّطات أكسيداز الأمين الأحادي (MAOIs)</p><p>أطلب من أخصائي الرعاية الطبية &nbsp;أو الصيدلي لائحة بهذه الأدوية إذا لم تكن متأكّدًا.</p><p dir="RTL">إعرف الأدوية التي تأخذها. احتفظ بقائمة بها واستشر أخصائي الرعاية الطبية أو الصيدليّ الخاص بك عندما تحصل على دواء جديد.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>أدوية أخرى</strong><strong> </strong><strong>و</strong><strong>رايفو</strong></p><p dir="RTL"><u>استخدام أدوية أخرى أو مكمّلات عشبيّة أو غذائية</u></p><p>لا ينبغي بك أن تأخذ أدوية أخرى تجعلك تشعر بالنعاس وأنت تأخذ رايفو.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>استخدام</u><u> رايفو</u><u> مع الطعام والشراب</u></p><p>يمكن أخذ اللاسميديتان مع الطعام أو بدونه. لا ينبغي بك شرب الكحول وأنت تأخذ رايفو.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>الحمل والإرضاع</u></p><p dir="RTL"><u>قبل أن تأخذ رايفو، أعلم طبيبك بكلّ الحالات الطبيّة التي تعاني منها، بما في ذلك</u><u> </u><u>إذا كنت:</u></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حاملاً أو كنت تخططين للحمل. من غير المعروف ما إذا كان رايفو قد يؤذي الجنين.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنتِ تُرضعين أو تنوين الإرضاع. من غير المعروف ما إذا كان رايفو ينتقل عبر حليب الثدي.</p><p>&nbsp;</p><p dir="RTL"><u>القيادة وتشغيل الآلات</u></p><p dir="RTL">ما هي أهم المعلومات التي يجب أن أعرفها عن رايفو؟</p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>لا </strong>تقد السيّارة أو تشغّل الآلات لثماني ساعات على الأقلّ بعد أن تأخذ رايفو، حتّى ولو كنت تشعر أنّك بخير.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا ينبغي بك أخذ رايفو إذا لم تكن قادرًا على الانتظار 8 ساعات على الأقلّ بين أخذ رايفو والقيادة أو تشغيل الآلات.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>التعاطي المفرط للدواء والإدمان </u></p><p dir="RTL">التعاطي المفرط للدواء</p><p dir="RTL">التعاطي المفرط للدواء هو الاستخدام المتعمد وغير العلاجي للدواء، ولو لمرة واحدة، لتأثيراته النفسية أو الفيزيولوجية المرغوبة.</p><p dir="RTL">في دراسة لإمكانية التعاطي المفرط للدواء عند الإنسان (HAP)، تم مقارنة جرعات علاجية أحادية (100 و200 ملغ) عن طريق الفم وجرعة علاجية (400 ملغ) من رايفو مع ألبرازولام (2 ملغ) (C-IV) والدواء الوهمي لدى مستخدمي أدوية متعددة ترفيهية (ن = 58). مع جميع جرعات رايفو ، أفاد الأشخاص تحت الدراسة &quot;تعلقهم بالدواء&quot; بنسبة ذات دلالة إحصائية أعلى من الدواء الوهمي، مما يشير إلى أن رايفو له احتمالية دفع الشخص للتعاطي المفرط للدواء. بالمقارنة مع الألبرازولام، أفاد الأشخاص الذين حصلوا على رايفو عن نتائج &quot;تعلق بالدواء&quot; بنسبة ذات دلالة إحصائية أقل. في دراسة HAP، حدث مزاج مبهج بنفس المدى لدى استعمال رايفو 200 ملغ ورايفو &nbsp;400ملغ مقارنة مع ألبرازولام 2 ملغ (43-49٪). ولوحظ شعور بالإسترخاء لدى عدد من الأشخاص الذين يستعملون الألبرازولام (22.6٪) أكبر من عدد الأشخاص الذين يأخذون أي جرعة من رايفو (7-11٪).</p><p dir="RTL">تشير دراسات الطور 2 و 3 إلى أنه في الجرعات العلاجية، نتج عن استعمال رايفو آثار جانبية تتمثل في النشوة والهلوسة بوتيرة أكبر من الدواء الوهمي، ومع ذلك تحدث هذه الآثار بوتيرة منخفضة (حوالي 1٪ من المرضى).</p><p dir="RTL">يجب تقييم خطر تعاطي المرضى المفرط للدواء ومتابعتهم بحثًا عن علامات سوء استخدام لاسميديتان أو تعاطيه المفرط.</p><p dir="RTL">الإدمان</p><p dir="RTL">لم يلاحظ انسحاب الدواء من الجسم في الأشخاص الأصحاء بعد التوقف المفاجئ بعد 7 جرعات يومية من اللاسميديتان 200 ملغ أو 400 ملغ.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يجب أن تأخذ دائما هذا الدواء تماما كما وصفه لك طبيبك أو الصيدلي. استشر طبيبك أو الصيدلي إذا كنت غير متأكد.</p><p dir="RTL">الجرعة الموصى بها من رايفو هي 50 ملغ، 100 ملغ، أو 200 ملغ، تؤخذ عن طريق الفم، حسب الحاجة. لا ينبغي أن تؤخذ أكثر من جرعة واحدة في غضون 24 ساعة، ولا ينبغي أن لا يؤخذ رايفو إلا إذا كان المريض يستطيع الانتظار لمدة 8 ساعات على الأقل بين الجرعة وقيادة السيارة أو تشغيل الآلات</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; خذ رايفو تمامًا حسب ارشادات طبيبك المعالج.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قد يعدّل طبيبك جرعتك. لا تغيّر جرعتك بدون استشارة طبيبك أوّلاً.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; خذ أقراص رايفو عن طريق الفم مع الطعام أو بدونه.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قم بابتلاع أقراص رايفو كاملة. &nbsp;لا تقسم أو تسحق أو تمضغ.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تأخذ أكثر من جرعة واحدة في فترة 24 ساعة.</p><p dir="RTL">&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;o إذا كنت تأخذ رايفو 50 ملغ أو 100 ملغ أو 200 ملغ وصداعك يختفي ثمّ يعود، لا ينبغي بك أخذ جرعة ثانية في خلال 24 ساعة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قد يُصاب بعض الأشخاص الذين يأخذون الكثير من أقراص رايفو بصداع أسوأ (الصداع الناتج عن الإفراط في أخذ الدواء). إذا ازداد صداعك، يمكن أن يقرّر طبيبك إيقاف علاجك برايفو.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يجب أن تدوّن متى تصاب بالصداع ومتى تأخذ رايفو لكي تستطيع التحدّث إلى طبيبك حول مفعول رايفو بالنسبة إليك.</p><p dir="RTL"><strong>في حال تناول كمية من رايفو تفوق الجرعة المحدّدة.</strong></p><p dir="RTL">إنَ التجارب السريريَة حول فرط جرعة اللاسميديتان محدودة. في حالة الجرعة المفرطة، يجب مراقبة المريض لرصد أيّ علامات أو عوارض ردود فعل سلبيّة ويجب اعتماد علاج داعم حسب الاقتضاء. ما من ترياق معروف لفرط جرعة اللاسميديتان.&nbsp;&nbsp;&nbsp;&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إذا كنت قد نسيت أن تتناول رايفو</strong></p><p dir="RTL">غير قابل للتطبيق</p><p><strong>&nbsp;</strong></p><p dir="RTL"><strong>إذا توقفت عن تناول رايفو</strong></p><p dir="RTL">في دراسة حول إساءة استعمال بشريّة محتملة للدواء لدى مستعملي مخدّرات ترفيهيّة، تمّ ربط جرعات من لاسميديتان من 100 أو 200 ملغ مع تعلّق أكبر بالدواء مقارنة بالدواء الوهمي. وفي دراسة منفصلة، لم يرد دليل على انسحاب جسديّ لدى مشاركين أصحّاء بعد التوقّف المفاجئ عن أخذ الدواء.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">على غرار جميع الأدوية، قد يسبّب رايفو آثارًا جانبية، و إن لم تكن تصيب الجميع.</p><p dir="RTL">يمكن أن يسبّب رايفو آثارًا جانبيّة خطيرة تتضمّن:</p><p><strong>انظر</strong><strong> </strong><strong>الفقرة </strong><strong>&ldquo;</strong><strong>ما هي أهم المعلومات التي يجب أن أعرفها عن رايفو؟</strong><strong> &ldquo;</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>تناذر السيروتونين. </strong>تناذر السيروتونين هو مشكلة نادرة ولكن خطيرة يمكن أن تحصل لدى الأشخاص الذين يستعملون رايفو، بخاصة إذا استُعمل رايفو مع أدوية مضادة للاكتئاب تُسمّى المثبّطات الانتقائيّة لإعادة قبط السيروتونين أو مثبّطات إعادة قبط السيروتونين النوريبينفرين. اتصل بطبيبك على الفور إذا أصبت بأيّ من عوارض تناذر السيروتونين التالية:</p><p dir="RTL">&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; - تغييرات عقليّة أو رؤية أشياء غير موجودة (هلوسات)، تهيّج أو غيبوبة</p><p dir="RTL">&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; - تسارع في نبضات القلب</p><p dir="RTL">&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; - تغيّر في ضغط الدم</p><p dir="RTL">&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; - ارتفاع حرارة الجسم</p><p dir="RTL">&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; - عضلات مشدودة</p><p dir="RTL">&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; - صعوبة في السير</p><p dir="RTL">&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; - غثيان، تقيؤ أو إسهال</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>الصداع الناتج عن الإفراط في أخذ الدواء</strong>. قد يُصاب بعض الأشخاص الذين يأخذون أدوية مثل رايفو لعلاج نوبات الصداع النصفي الحاد لعشرة أيّام أو أكثر كلّ شهر، بصداع أسوأ (الصداع الناتج عن الإفراط في أخذ الدواء). إذا ازداد صداعك سوءًا، قد يقرّر طبيبك إيقاف علاجك برايفو.</p><p dir="RTL"><strong>تتضمّن</strong><strong> </strong><strong>آثار رايفو الجانبيّة</strong><strong> </strong><strong>الأكثر</strong><strong> </strong><strong>شيوعًا</strong><strong> </strong><strong>ما</strong><strong> </strong><strong>يلي:</strong></p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الوخز</p></td><td style="vertical-align:top"><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الخدر</p></td><td style="vertical-align:top"><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الدوخة</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بالتعب</p></td><td style="vertical-align:top"><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; النعاس</p></td></tr></tbody></table><p>&nbsp;</p><p dir="RTL">أعلم مقدّم الرعاية الصحيّة بأيّ أثر جانبي قد يزعجك أو قد لا يزول.</p><p dir="RTL">لا تقتصر الآثار الجانبيّة لرايفو على ما سبق ذكره فحسب. للمزيد من المعلومات، إسأل أخصّائي الرعاية الصحيّة أو الصّيدلي.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا أصبحت أي من الآثار الجانبية خطيرة، أو إذا لاحظت أي آثار جانبية غير مدرجة في هذه النشرة، فيرجى إخبار طبيبك أو مقدم الرعاية الصحية أو الصيدلي.</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>احفظ هذا الدواء بعيدا عن نظر ومتناول الأطفال</strong><strong>.</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">لا تستخدم هذا الدواء بعد تاريخ انتهاء صلاحيته المحدّد على<strong> </strong>العلبة<strong> .</strong>&rdquo;EXP.&ldquo; يشير تاريخ انتهاء الصلاحية إلى اليوم الأخير من الشهر.</p><p dir="RTL">يُحفظ في درجة حرارة أقل من 30 درجة مئوية<strong>.</strong></p><p dir="RTL">لا تتخلص من أي أدوية عن طريق مياه الصرف الصحي أو مع النفايات المنزلية. اسأل الصيدلي عن كيفية التخلص من الأدوية التي لم تعد تستخدمها. هذه التدابير سوف تساعد في حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>المادة</strong><strong> </strong><strong>الفاعلة</strong><strong>:</strong> هيميسوكسينات اللاسميديتان</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>المكوّنات غير الفاعلة: </strong>كروسكارميلوز الصوديوم، ستيارات المغنيزيوم، سلولوز دقيق البلوّريّة، نشا مسبق التهلمن، لوريل سلفات الصوديوم.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>مكوّنات مزيج اللون: </strong>أكسيد الحديديك الأسود، غليكول الإثيلين المتعدد، كحول البوليفينيل، طلق، ثاني أكسيد التيتانيوم. تحتوي أيضًا أقراص الـ 100 ملغ على أكسيد الحديديك الأحمر.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">أقراص رايفو (لاسميديتان) 50 ملغ هي أقراص رمادية فاتحة اللّون، بيضاوية الشكل ومغلّفة، مع &quot;L-50&rdquo; مخلوطة على جانب واحد و &quot;4312&quot; على الجانب الآخر.</p><p dir="RTL">أقراص رايفو (لاسميديتان) 100 ملغ هي أقراص أرجوانية فاتحة اللّون، بيضاوي الشكل ومغلّفة، وأقراص مع &quot; &ldquo;L-100مخلوطة على جانب واحد و &quot;4491&quot; على الجانب الآخر.</p><p dir="RTL">&nbsp;</p><p dir="RTL">رايفو متوفر في عبوات تحتوي على 4 و 8 و 12 حبة.</p><p dir="RTL">قد لا يتم تسويق جميع جرعات وأحجام العبوات.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">حامل رخصة التسويق:</p><p dir="RTL">شركة إيلي ليلي وشركاه. مركز الشركة ليلي إنديانابوليس، ولاية إنديانا 46285، الولايات المتّحدة الأمريكية.</p><p dir="RTL">المصنِّع:</p><p dir="RTL">ليلي دل كريبي، &nbsp;Inc.طريق &nbsp;65إنفنتري 12,6 كلم، كرولينا بويرتو ريكو00985 ، الولايات المتّحدة الأمريكية.</p><p dir="RTL">موقع التغليف والتعبئة:</p><p dir="RTL">شركة إيلي ليلي وشركاه. مركز الشركة ليلي إنديانابوليس، ولاية إنديانا 46285، الولايات المتّحدة الأمريكية.</p><p>&nbsp;</p><p dir="RTL">للحصول على أيّ معلومات تتعلّق بهذا الدواء، يُرجى الاتصال بالممثل المحلّي لحامل رخصة التسويق:</p><p dir="RTL">إيلي ليلي وشركاه - المملكة العربية السعودية</p><p dir="RTL">صندوق البريد 92120</p><p dir="RTL">الطابق 16، رقم المبنى 3074</p><p dir="RTL">البرجB<strong> </strong>، أبراج العليا</p><p dir="RTL">شارع الأمير محمد بن عبد العزيز</p><p dir="RTL">العليا، الرياض</p><p dir="RTL">المملكة العربية السعودية</p><p dir="RTL">الخط المباشر:+966 11 461 7800 ،+966 11 4617850</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            تاريخ الإصدار: جون 2021
النسخة 2
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                REYVOW (lasmiditan) 50 mg and 100 mg tablets, for oral use.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                2.1	General description

REYVOW (lasmiditan) is a serotonin (5-HT) 1F receptor agonist for oral administration. The chemical name of lasmiditan hemisuccinate is 2,4,6-trifluoro-N-[6-(1-methylpiperidine-4 carbonyl) pyridine-2-yl] benzamide hemisuccinate. It has the empirical formula of C19H18F3N3O2•0.5[C4H6O4] and a molecular weight of 436.41 (hemisuccinate). Lasmiditan hemisuccinate has the following structural formula:

 

Lasmiditan hemisuccinate is a white, crystalline powder that is sparingly soluble in water, slightly soluble in ethanol, and soluble in methanol. A 1 mg/mL aqueous solution of lasmiditan hemisuccinate has a pH of 6.8 at ambient conditions.

2.2	Qualitative and quantitative composition

REYVOW 50 mg tablets contain 50 mg lasmiditan (equivalent to 57.824 mg lasmiditan hemisuccinate) and the inactive ingredients as follows:
Excipients – croscarmellose sodium, magnesium stearate, microcrystalline cellulose, pregelatinized starch, sodium lauryl sulfate.
Color mixture ingredients – black ferric oxide, polyethylene glycol, polyvinyl alcohol, talc, titanium dioxide.
REYVOW 100 mg tablets contain 100 mg lasmiditan (equivalent to 115.65 mg lasmiditan hemisuccinate) and the inactive ingredients as follows:
Excipients – croscarmellose sodium, magnesium stearate, microcrystalline cellulose, pregelatinized starch, sodium lauryl sulfate.
Color mixture ingredients – black ferric oxide, polyethylene glycol, polyvinyl alcohol, red ferric oxide, talc, titanium dioxide.

For the full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                REYVOW (lasmiditan) tablets are available in two strengths:
•	50 mg tablet: light gray, oval, film coated, tablets with “L-50” debossed on one side and “4312” on the other
•	100 mg tablet: light purple, oval, film coated, tablets with “L-100” debossed on one side and “4491” on the other

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">REYVOW<sup>&reg;</sup>&nbsp;is indicated for the acute treatment of migraine with or without aura in adults.</p><p dir="ltr">Limitations of Use</p><p dir="ltr">REYVOW is not indicated for the preventive treatment of migraine.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">The recommended dose of REYVOW is 50&nbsp;mg, 100&nbsp;mg, or 200&nbsp;mg taken orally, as needed. No more than one dose should be taken in 24&nbsp;hours, and REYVOW should not be taken unless the patient can wait at least 8&nbsp;hours between dosing and driving or operating machinery <em>[see Special warnings and precautions for use (4.4)].</em></p><p dir="ltr">A second dose of REYVOW has not been shown to be effective for the same migraine attack.</p><p dir="ltr">The safety of treating an average of more than 4 migraine attacks in a 30-day period has not been established.</p><p dir="ltr">REYVOW may be taken with or without food.</p><p>Administer tablets whole; do not split, crush, or chew.</p><p dir="ltr">USE IN SPECIFIC POPULATIONS</p><p dir="ltr"><em>Pediatric Use</em></p><p dir="ltr">Safety and effectiveness in pediatric patients have not been established.</p><p dir="ltr"><em>Geriatric Use</em></p><p dir="ltr">In controlled clinical trials, dizziness occurred more frequently in patients who were at least 65&nbsp;years of age (19% for REYVOW, 2% for placebo) compared to patients who were less than 65&nbsp;years of age (14% for REYVOW, 3% for placebo). A larger increase in systolic blood pressure also occurred in patients 65&nbsp;years of age and older compared to patients who were less than 65&nbsp;years of age <em>[see Undesirable effects (4.8)]</em>. Clinical studies of REYVOW did not include sufficient numbers of subjects aged 65 and over to determine whether there is a difference in efficacy in these patients compared to younger subjects. However, in clinical pharmacology studies, no clinically relevant effect on exposure to REYVOW was observed in elderly subjects <em>[see PHARMACOLOGICAL PROPERTIES (5)]</em>. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.</p><p dir="ltr"><em>Hepatic Impairment</em></p><p dir="ltr">No dosage adjustment is needed for patients with mild or moderate hepatic impairment (Child-Pugh A or B). REYVOW has not been studied in patients with severe hepatic impairment (Child-Pugh C) and its use in these patients is not recommended.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                None.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr"><em>Driving Impairment</em></p><p dir="ltr">REYVOW may cause significant driving impairment. In a driving study, administration of single 50&nbsp;mg, 100&nbsp;mg, or 200&nbsp;mg doses of REYVOW significantly impaired subjects&rsquo; ability to drive <em>[see Pharmacodynamic properties (5.1)]</em>. Additionally, more sleepiness was reported at 8&nbsp;hours following a single dose of REYVOW compared to placebo. Advise patients not to engage in potentially hazardous activities requiring complete mental alertness, such as driving a motor vehicle or operating machinery, for at least 8&nbsp;hours after each dose of REYVOW. Patients who cannot follow this advice should not take REYVOW. Prescribers and patients should be aware that patients may not be able to assess their own driving competence and the degree of impairment caused by REYVOW.</p><p dir="ltr"><em>Central Nervous System Depression</em></p><p dir="ltr">REYVOW may cause central nervous system (CNS) depression, including dizziness and sedation <em>[see Undesirable effects (4.8)]</em>.</p><p dir="ltr">Because of the potential for REYVOW to cause sedation, other cognitive and/or neuropsychiatric adverse reactions, and driving impairment, REYVOW should be used with caution if used in combination with alcohol or other CNS depressants <em>[see Interaction with other medicinal products and other forms of interaction (4.5)]</em>. Patients should be warned against driving and other activities requiring complete mental alertness for at least 8&nbsp;hours after REYVOW is taken <em>[see Special warnings and precautions for use (4.4)].</em></p><p dir="ltr"><em>Serotonin Syndrome</em></p><p dir="ltr">In clinical trials, reactions consistent with serotonin syndrome were reported in patients treated with REYVOW who were not taking any other drugs associated with serotonin syndrome. Serotonin syndrome may also occur with REYVOW during coadministration with serotonergic drugs [e.g., selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), and monoamine oxidase (MAO) inhibitors]. Serotonin syndrome symptoms may include mental status changes (e.g., agitation, hallucinations, coma), autonomic instability (e.g., tachycardia, labile blood pressure, hyperthermia), neuromuscular signs (e.g., hyperreflexia, incoordination), and/or gastrointestinal signs and symptoms (e.g., nausea, vomiting, diarrhea). The onset of symptoms usually occurs within minutes to hours of receiving a new or a greater dose of a serotonergic medication. Discontinue REYVOW if serotonin syndrome is suspected.</p><p dir="ltr"><em>Medication Overuse Headache</em></p><p dir="ltr">Overuse of acute migraine drugs (e.g., ergotamines, triptans, opioids, or a combination of these drugs for 10 or more days per month) may lead to exacerbation of headache (i.e., medication overuse headache). Medication overuse headache may present as migraine-like daily headaches or as a marked increase in frequency of migraine attacks. Detoxification of patients including withdrawal of the overused drugs and treatment of withdrawal symptoms (which often includes a transient worsening of headache) may be necessary.</p><p dir="ltr"><em>Drug Abuse and Dependence</em></p><p dir="ltr">Abuse</p><p dir="ltr">Abuse is the intentional, non-therapeutic use of a drug, even once, for its desirable psychological or physiological effects. In a human abuse potential (HAP) study in recreational poly-drug users (n=58), single oral therapeutic doses (100 and 200&nbsp;mg) and a supratherapeutic dose (400&nbsp;mg) of REYVOW were compared to alprazolam (2&nbsp;mg) (C-IV) and placebo. With all doses of REYVOW, subjects reported statistically significantly higher &ldquo;drug liking&rdquo; scores than placebo, indicating that REYVOW has abuse potential. In comparison to alprazolam, subjects who received REYVOW reported statistically significantly lower &ldquo;drug liking&rdquo; scores. In the HAP study, euphoric mood occurred to a similar extent with REYVOW 200&nbsp;mg, REYVOW 400&nbsp;mg, and alprazolam 2&nbsp;mg (43-49%). A feeling of relaxation was noted in more subjects on alprazolam (22.6%) than with any dose of REYVOW (7-11%).</p><p dir="ltr">Phase 2 and 3 studies indicate that, at therapeutic doses, REYVOW produced adverse events of euphoria and hallucinations to a greater extent than placebo. However these events occur at a low frequency (about 1% of patients).</p><p dir="ltr">Evaluate patients for risk of drug abuse and observe them for signs of lasmiditan misuse or abuse.</p><p dir="ltr">Dependence</p><p dir="ltr">Physical withdrawal was not observed in healthy subjects following abrupt cessation after 7 daily doses of lasmiditan 200&nbsp;mg or 400&nbsp;mg.</p><p dir="ltr">&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr"><em>CNS Depressants</em></p><p dir="ltr">Concomitant administration of REYVOW and alcohol or other CNS depressant drugs has not been evaluated in clinical studies. Because of the potential of REYVOW to cause sedation, as well as other cognitive and/or neuropsychiatric adverse reactions, REYVOW should be used with caution if used in combination with alcohol or other CNS depressants <em>[see Special warnings and precautions for use (4.4)].</em></p><p dir="ltr"><em>Serotonergic Drugs</em></p><p dir="ltr">Concomitant administration of REYVOW and drugs (e.g., SSRIs, SNRIs, TCAs, MAO inhibitors, trazodone, etc.), over-the counter medications (e.g., dextromethorphan), or herbal supplements (e.g., St. John&rsquo;s Wort) that increase serotonin may increase the risk of serotonin syndrome <em>[see Special warnings and precautions for use (4.4)].&nbsp;</em>Use REYVOW with caution in patients taking medications that increase serotonin.</p><p dir="ltr"><em>Heart Rate Lowering Drugs</em></p><p dir="ltr">REYVOW has been associated with a lowering of heart rate <em>[see Undesirable effects (4.8)]</em>. In a drug interaction study, addition of a single 200&nbsp;mg dose of REYVOW to propranolol decreased heart rate by an additional 5&nbsp;beats per minute compared to propranolol alone, for a mean maximum of 19&nbsp;beats per minute. Use REYVOW with caution in patients taking concomitant medications that lower heart rate if this magnitude of heart rate decrease may pose a concern.</p><p><em>P-glycoprotein (P-gp) Transporter Substrates</em></p><p>Coadministration of REYVOW with P-gp substrates where a small change in substrate plasma concentration may lead to serious toxicities (e.g., digoxin) is not recommended <em>[see Pharmacokinetic properties (5.2)]</em>.</p><p>Lasmiditan inhibits P-glycoprotein (P-gp) in-vitro and increased the systemic exposure of coadministered dabigatran by approximately 25%. When lasmiditan is administered with P-gp substrates with a narrow therapeutic index (e.g., digoxin), the in-vivo effect could be clinically meaningful and caution is advised. Lasmiditan inhibits BCRP in-vitro although no significant change in rosuvastatin PK was observed when coadministered with lasmiditan. Lasmiditan inhibits OCT1 in-vitro although no change in sumatriptan PK was observed when coadministered with lasmiditan. Lasmiditan inhibits renal efflux transporters, MATE1 and MATE2-K, in-vitro. An assessment of creatinine renal clearance over time indicated a slight (11%) decrease without changes in GFR up to 24 hours after lasmiditan administration compared to placebo, which suggests that any effect of lasmiditan on metformin exposure would not be clinically significant.</p><p dir="ltr">&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr"><u>Pregnancy</u></p><p dir="ltr">Risk Summary</p><p dir="ltr">There are no adequate data on the developmental risk associated with the use of REYVOW in pregnant women. In animal studies, adverse effects on development (increased incidences of fetal abnormalities, increased embryofetal and offspring mortality, decreased fetal body weight) occurred at maternal exposures less than (rabbit) or greater than (rat) those observed clinically (see Data).</p><p dir="ltr">In the U.S. general population, the estimated background risk of major birth defects and of miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. The estimated rates of major birth defects (2.2% to 2.9%) and miscarriage (17%) among deliveries to women with migraine are similar to rates reported in women without migraine.</p><p dir="ltr">Clinical Considerations</p><p dir="ltr"><em>Disease-Associated Maternal and/or Embryo/Fetal Risk</em></p><p dir="ltr">Published data have suggested that women with migraine may be at increased risk for preeclampsia and gestational hypertension during pregnancy.</p><p dir="ltr">Data</p><p dir="ltr"><em>Animal Data</em></p><p dir="ltr">Oral administration of lasmiditan (0, 100, 175, or 250&nbsp;mg/kg/day) to pregnant rats throughout organogenesis resulted in increases in skeletal variations at the mid and high doses and reduced fetal body weight at the high dose. The high dose was associated with maternal toxicity. At the no-effect dose (100&nbsp;mg/kg/day) for adverse effects on embryofetal development in rats, plasma exposure (AUC) was approximately 10 times that in humans at the MRHD.</p><p dir="ltr">Oral administration of lasmiditan (0, 50, 75, or 115&nbsp;mg/kg/day) to pregnant rabbits throughout organogenesis resulted in malformations (skeletal and visceral), increases in skeletal variations and embryofetal mortality, and decreased fetal body weight at the highest dose tested, which was associated with maternal toxicity. Plasma exposure (AUC) at the no-effect dose (75&nbsp;mg/kg/day) for adverse effects on embryofetal development in rabbits was less than that in humans at the MRHD.</p><p dir="ltr">Oral administration of lasmiditan (0, 100, 150, or 225&nbsp;mg/kg/day) to rats throughout pregnancy and lactation resulted in increases in stillbirth and neonatal mortality at the highest dose tested, which was associated with maternal toxicity and delayed parturition. Plasma exposure (AUC) at the no-effect dose (150&nbsp;mg/kg/day) for adverse effects on pre- and postnatal development was approximately 16 times that in humans at the MRHD.</p><p dir="ltr"><u>Lactation</u></p><p dir="ltr">Risk Summary</p><p dir="ltr">There are no data on the presence of lasmiditan in human milk, the effects of lasmiditan on the breastfed infant, or the effects of lasmiditan on milk production. Excretion of lasmiditan and/or metabolites into milk, at levels approximately 3 times those in maternal plasma, was observed in lactating rats following oral administration of lasmiditan.</p><p dir="ltr">The developmental and health benefits of breastfeeding should be considered along with the mother&rsquo;s clinical need for REYVOW and any potential adverse effects on the breastfed infant from REYVOW or from the underlying maternal condition.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">Lasmiditan is associated with Central Nervous System adverse reactions. In a driving study,</p><p dir="ltr">lasmiditan significantly impaired the ability to drive. Advise patients not to drive or engage in other activities requiring heightened attention until at least 8 hours after taking each dose of lasmiditan, even if they feel well enough to do so. Patients who cannot follow this advice should not take lasmiditan.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">The following clinically significant adverse reactions are described elsewhere in the labeling:</p><p dir="ltr">&bull;&nbsp;&nbsp;&nbsp;&nbsp; Driving Impairment <em>[see Special warnings and precautions for use (4.4)]</em></p><p dir="ltr">&bull;&nbsp;&nbsp;&nbsp;&nbsp; Central Nervous System Depression <em>[see Special warnings and precautions for use (4.4)]</em></p><p dir="ltr">&bull;&nbsp;&nbsp;&nbsp;&nbsp; Serotonin Syndrome <em>[see Special warnings and precautions for use (4.4)]</em></p><p dir="ltr">&bull;&nbsp;&nbsp;&nbsp;&nbsp; Medication Overuse Headache <em>[see Special warnings and precautions for use (4.4)]</em></p><p dir="ltr"><strong>&nbsp;</strong></p><p dir="ltr"><strong>Clinical Trials Experience</strong></p><p dir="ltr">Because clinical studies are conducted under widely varying conditions, adverse reaction rates observed in the clinical studies of a drug cannot be directly compared to rates in the clinical studies of another drug and may not reflect the rates observed in practice.</p><p dir="ltr">The safety of REYVOW has been evaluated in 4,878 subjects who received at least one dose of REYVOW. In 2 placebo-controlled, Phase 3 trials in adult patients with migraine (Studies 1 and 2), a total of 3,177 patients received REYVOW 50, 100, or 200&nbsp;mg <em>[see </em>Pharmacodynamic properties<em> (5.1)]</em>. Of the REYVOW-treated patients in these 2 studies, approximately 84% were female, 78% were White, 18% were Black, and 18% were of Hispanic or Latino ethnicity. The mean age at study entry was 42.4&nbsp;years (range 18 to 81).</p><p dir="ltr">Long-term safety was assessed for 2,030 patients, dosing intermittently for up to 12&nbsp;months in a long-term safety study. Of these, 728 patients were exposed to 100&nbsp;mg or 200&nbsp;mg for at least 3&nbsp;months, 361 patients were exposed to these doses for at least 6&nbsp;months, and 180 patients were exposed to these doses for at least 12&nbsp;months, all of whom treated at least 2 migraine attacks per month on average. In that study, 14% (148 out of 1,039) in the 200&nbsp;mg dose group, and 11% (112 out of 991) in the 100&nbsp;mg dose group withdrew from the trial because of an adverse event. The most common adverse event resulting in discontinuation in the long-term safety study (greater than 2%) was dizziness.</p><p dir="ltr">Table 1 shows adverse reactions that occurred in at least 2% of patients treated with REYVOW and more frequently than in patients who received placebo in Studies 1 and 2. The most common adverse reactions (at least 5%) were dizziness, fatigue, paresthesia, and sedation.</p><p dir="ltr">Table 1: Adverse Reactions Occurring in &ge;2% and at a Frequency Greater than Placebo in Studies 1 and 2</p><table border="1" cellspacing="0" cellpadding="0" dir="ltr"><tbody><tr><td style="vertical-align:top"><p><strong>Adverse Reaction</strong></p></td><td style="vertical-align:top"><p><strong>REYVOW 50&nbsp;mg<br />N=654<br />%</strong></p></td><td style="vertical-align:top"><p><strong>REYVOW 100&nbsp;mg<br />N=1265<br />%</strong></p></td><td style="vertical-align:top"><p><strong>REYVOW 200&nbsp;mg<br />N=1258<br />%</strong></p></td><td style="vertical-align:top"><p><strong>Placebo<br />N=1262<br />%</strong></p></td></tr><tr><td style="vertical-align:top"><p>Dizziness</p></td><td style="vertical-align:top"><p>9</p></td><td style="vertical-align:top"><p>15</p></td><td style="vertical-align:top"><p>17</p></td><td style="vertical-align:top"><p>3</p></td></tr><tr><td style="vertical-align:top"><p>Fatigue<sup>a</sup></p></td><td style="vertical-align:top"><p>4</p></td><td style="vertical-align:top"><p>5</p></td><td style="vertical-align:top"><p>6</p></td><td style="vertical-align:top"><p>1</p></td></tr><tr><td style="vertical-align:top"><p>Paresthesia<sup>b</sup></p></td><td style="vertical-align:top"><p>3</p></td><td style="vertical-align:top"><p>7</p></td><td style="vertical-align:top"><p>9</p></td><td style="vertical-align:top"><p>2</p></td></tr><tr><td style="vertical-align:top"><p>Sedation<sup>c</sup></p></td><td style="vertical-align:top"><p>6</p></td><td style="vertical-align:top"><p>6</p></td><td style="vertical-align:top"><p>7</p></td><td style="vertical-align:top"><p>2</p></td></tr><tr><td style="vertical-align:top"><p>Nausea and/or Vomiting</p></td><td style="vertical-align:top"><p>3</p></td><td style="vertical-align:top"><p>4</p></td><td style="vertical-align:top"><p>4</p></td><td style="vertical-align:top"><p>2</p></td></tr><tr><td style="vertical-align:top"><p>Muscle Weakness</p></td><td style="vertical-align:top"><p>1</p></td><td style="vertical-align:top"><p>1</p></td><td style="vertical-align:top"><p>2</p></td><td style="vertical-align:top"><p>0</p></td></tr></tbody></table><p dir="ltr"><sup>a</sup>&nbsp;&nbsp;&nbsp; Fatigue includes the adverse reaction related terms asthenia and malaise.</p><p dir="ltr"><sup>b</sup>&nbsp;&nbsp;&nbsp; Paresthesia includes the adverse reaction related terms paresthesia oral, hypoesthesia, and hypoesthesia oral.</p><p dir="ltr"><sup>c</sup>&nbsp;&nbsp;&nbsp; Sedation includes the adverse reaction related term somnolence.</p><p dir="ltr">Less Common Adverse Reactions</p><p dir="ltr">The following adverse reactions occurred in less than 2% of REYVOW-treated patients but more frequently than in patients receiving placebo: vertigo, incoordination, lethargy, visual impairment, feeling abnormal, feeling hot or feeling cold, palpitations, anxiety, tremor, restlessness, sleep abnormalities including sleep disturbance and abnormal dreams, muscle spasm, limb discomfort, cognitive changes, confusion, euphoric mood, chest discomfort, speech abnormalities, dyspnea, and hallucinations.</p><p dir="ltr"><em>Hypersensitivity</em></p><p dir="ltr">Events of hypersensitivity, including angioedema, rash and photosensitivity reaction, occurred in patients treated with REYVOW. In controlled trials, hypersensitivity was reported in 0.2% of patients treated with REYVOW compared to no patients who received placebo. If a serious or severe hypersensitivity reaction occurs, initiate appropriate therapy and discontinue administration of REYVOW.</p><p dir="ltr">Vital Sign Changes</p><p dir="ltr"><em>Heart Rate Decrease</em></p><p dir="ltr">REYVOW was associated with mean decreases in heart rate of 5 to 10&nbsp;beats per minute (bpm) while placebo was associated with mean decreases of 2 to 5&nbsp;bpm. Consider evaluating heart rate after administration of REYVOW in patients for whom these changes may not be tolerated, including patients taking other medications that lower heart rate <em>[see </em>Interaction with other medicinal products and other forms of interaction<em> (4.5)]</em>.</p><p dir="ltr"><em>Blood Pressure Increase</em></p><p dir="ltr">REYVOW may increase blood pressure following a single dose. In non-elderly healthy volunteers there was a mean increase from baseline in ambulatory systolic and diastolic blood pressure of approximately 2 to 3&nbsp;mm&nbsp;Hg one&nbsp;hour after administration of 200&nbsp;mg REYVOW compared to a mean increase of up to 1&nbsp;mm&nbsp;Hg for placebo. In healthy volunteers over 65&nbsp;years of age, there was a mean increase from baseline in ambulatory systolic blood pressure of 7&nbsp;mm&nbsp;Hg one&nbsp;hour after administration of 200&nbsp;mg REYVOW compared to a mean increase of 4&nbsp;mm&nbsp;Hg for placebo. By 2&nbsp;hours, there were no increases in mean blood pressure with REYVOW compared to placebo. REYVOW has not been well studied in patients with ischemic heart disease. Consider evaluating blood pressure after administration of REYVOW in patients for whom these changes may not be tolerated.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><strong>Reporting of suspected adverse reactions</strong></p><p dir="ltr">Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the</p><p dir="ltr">national reporting system listed below.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><strong>To report any side effect(s):</strong></p><p dir="ltr"><strong>&nbsp;</strong></p><p dir="ltr">The National Pharmacovigilance and Drug Safety Center (NPC):</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Fax: +966-11-205-7662</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Call NPC at +966-11-2038222. Ext: 2317-2356-2340</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;SFDA Call Center: 19999</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; E-mail: npc.drug@sfda.gov.sa</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Website: &nbsp;https://ade.sfda.gov.sa/</p><p dir="ltr">&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">There is limited clinical trial experience with lasmiditan overdose. In case of an overdose, monitor</p><p dir="ltr">the patient for any signs or symptoms of adverse reactions and institute supportive treatment as</p><p dir="ltr">appropriate. There is no known antidote to lasmiditan overdose.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">Pharmacotherapeutic group: {group}, ATC code: {code} &lt;not yet assigned&gt;</p><p dir="ltr"><u>Mechanism of Action</u></p><p dir="ltr">Lasmiditan binds with high affinity to the 5-HT<sub>1F</sub> receptor. Lasmiditan presumably exerts its therapeutic effects in the treatment of migraine through agonist effects at the 5-HT<sub>1F</sub> receptor; however, the precise mechanism is unknown.</p><p dir="ltr"><u>Pharmacodynamics</u></p><p dir="ltr"><em>Cardiac Electrophysiology</em></p><p dir="ltr">At a dose two times the maximum recommended daily dose, REYVOW does not prolong the QTc interval to any clinically relevant extent.</p><p dir="ltr"><u>Clinical Studies</u></p><p dir="ltr"><em>Migraine</em></p><p dir="ltr">The efficacy of REYVOW in the acute treatment of migraine was demonstrated in two randomized, double-blind, placebo-controlled trials [Study 1 (NCT02439320) and Study 2 (NCT02605174)]. These studies enrolled patients with a history of migraine with and without aura according to the International Classification of Headache Disorders (ICHD-II) diagnostic criteria. Patients were predominantly female (84%), and White (78%), with a mean age of 42&nbsp;years (range 18-81). Twenty-two percent of patients were taking preventive medication for migraine at baseline. Study 1 randomized patients to REYVOW 100&nbsp;mg (n=744), or 200 mg (n=745) or placebo (n=742) and Study 2 randomized patients to REYVOW 50&nbsp;mg (n=750), 100&nbsp;mg (n=754), or 200&nbsp;mg (n=750) or placebo (n=751). Patients were allowed to take a rescue medication 2&nbsp;hours after taking study drug; however, opioids, barbiturates, triptans, and ergots were not allowed within 24&nbsp;hours of study drug administration.</p><p dir="ltr">The primary efficacy analyses were conducted in patients that treated a migraine with moderate to severe pain within 4&nbsp;hours of the onset of the attack. The efficacy of REYVOW was established by an effect on pain freedom at 2&nbsp;hours and Most Bothersome Symptom (MBS) freedom at 2&nbsp;hours compared to placebo for Studies 1 and 2. Pain freedom was defined as a reduction of moderate or severe headache pain to no pain, and MBS freedom was defined as the absence of the self-identified MBS (photophobia, phonophobia, or nausea). Among patients who selected an MBS, the most commonly selected MBS was photophobia (54%), followed by nausea (24%), and phonophobia (22%).</p><p dir="ltr">In both studies, the percentage of patients achieving pain freedom and MBS freedom 2&nbsp;hours after treatment was significantly greater among patients receiving REYVOW at all doses compared to those receiving placebo (see Table 2).</p><p dir="ltr">&nbsp;</p><p dir="ltr">Table 2: Migraine Efficacy Endpoints after Treatment for Studies 1 and 2</p><table border="1" cellspacing="0" cellpadding="0" dir="ltr" style="width:738px"><tbody><tr><td rowspan="2" style="vertical-align:top"><p>&nbsp;</p></td><td colspan="3" style="vertical-align:top"><p><strong>Study 1</strong></p></td><td colspan="4" style="vertical-align:top"><p><strong>Study 2</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>REYVOW<br />100&nbsp;mg</strong></p></td><td style="vertical-align:top"><p><strong>REYVOW<br />200&nbsp;mg</strong></p></td><td style="vertical-align:top"><p><strong>Placebo</strong></p></td><td style="vertical-align:top"><p><strong>REYVOW<br />50&nbsp;mg</strong></p></td><td style="vertical-align:top"><p><strong>REYVOW<br />100&nbsp;mg</strong></p></td><td style="vertical-align:top"><p><strong>REYVOW<br />200&nbsp;mg</strong></p></td><td style="vertical-align:top"><p><strong>Placebo</strong></p></td></tr><tr><td colspan="8" style="vertical-align:top"><p><strong>Pain Free at 2 hours</strong></p></td></tr><tr><td style="vertical-align:top"><p>N</p></td><td style="vertical-align:top"><p>498</p></td><td style="vertical-align:top"><p>503</p></td><td style="vertical-align:top"><p>515</p></td><td style="vertical-align:top"><p>544</p></td><td style="vertical-align:top"><p>523</p></td><td style="vertical-align:top"><p>521</p></td><td style="vertical-align:top"><p>534</p></td></tr><tr><td style="vertical-align:top"><p>% Responders</p></td><td style="vertical-align:top"><p>28.3</p></td><td style="vertical-align:top"><p>31.8</p></td><td style="vertical-align:top"><p>15.3</p></td><td style="vertical-align:top"><p>28.3</p></td><td style="vertical-align:top"><p>31.4</p></td><td style="vertical-align:top"><p>38.8</p></td><td style="vertical-align:top"><p>21.0</p></td></tr><tr><td style="vertical-align:top"><p>Difference from placebo (%)</p></td><td style="vertical-align:top"><p>13</p></td><td style="vertical-align:top"><p>16.5</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>7.3</p></td><td style="vertical-align:top"><p>10.4</p></td><td style="vertical-align:top"><p>17.8</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><em>p</em>-value</p></td><td style="vertical-align:top"><p>&lt;0.001</p></td><td style="vertical-align:top"><p>&lt;0.001</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>0.006</p></td><td style="vertical-align:top"><p>&lt;0.001</p></td><td style="vertical-align:top"><p>&lt;0.001</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td colspan="8" style="vertical-align:top"><p><strong>MBS Free at 2 hours</strong></p></td></tr><tr><td style="vertical-align:top"><p>N</p></td><td style="vertical-align:top"><p>464</p></td><td style="vertical-align:top"><p>467</p></td><td style="vertical-align:top"><p>480</p></td><td style="vertical-align:top"><p>502</p></td><td style="vertical-align:top"><p>491</p></td><td style="vertical-align:top"><p>478</p></td><td style="vertical-align:top"><p>509</p></td></tr><tr><td style="vertical-align:top"><p>% Responders</p></td><td style="vertical-align:top"><p>41.2</p></td><td style="vertical-align:top"><p>40.7</p></td><td style="vertical-align:top"><p>29.6</p></td><td style="vertical-align:top"><p>40.8</p></td><td style="vertical-align:top"><p>44.0</p></td><td style="vertical-align:top"><p>48.7</p></td><td style="vertical-align:top"><p>33.2</p></td></tr><tr><td style="vertical-align:top"><p>Difference from placebo (%)</p></td><td style="vertical-align:top"><p>11.6</p></td><td style="vertical-align:top"><p>11.1</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>7.6</p></td><td style="vertical-align:top"><p>10.8</p></td><td style="vertical-align:top"><p>15.5</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><em>p</em>-value</p></td><td style="vertical-align:top"><p>&lt;0.001</p></td><td style="vertical-align:top"><p>&lt;0.001</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>0.014</p></td><td style="vertical-align:top"><p>&lt;0.001</p></td><td style="vertical-align:top"><p>&lt;0.001</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr></tbody></table><p dir="ltr">&nbsp;</p><p dir="ltr">Pain relief at 2&nbsp;hours, defined as a reduction in migraine pain from moderate or severe to mild or none, was also evaluated (see Table 3).</p><p dir="ltr">&nbsp;</p><p dir="ltr">Table 3: Additional Migraine Efficacy Endpoint after Treatment for Studies 1 and 2</p><table border="1" cellspacing="0" cellpadding="0" dir="ltr" style="width:738px"><tbody><tr><td rowspan="2" style="vertical-align:top"><p>&nbsp;</p></td><td colspan="3" style="vertical-align:top"><p><strong>Study 1</strong></p></td><td colspan="4" style="vertical-align:top"><p><strong>Study 2</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>REYVOW<br />100&nbsp;mg</strong></p></td><td style="vertical-align:top"><p><strong>REYVOW<br />200&nbsp;mg</strong></p></td><td style="vertical-align:top"><p><strong>Placebo</strong></p></td><td style="vertical-align:top"><p><strong>REYVOW<br />50&nbsp;mg</strong></p></td><td style="vertical-align:top"><p><strong>REYVOW<br />100&nbsp;mg</strong></p></td><td style="vertical-align:top"><p><strong>REYVOW<br />200&nbsp;mg</strong></p></td><td style="vertical-align:top"><p><strong>Placebo</strong></p></td></tr><tr><td colspan="8" style="vertical-align:top"><p><strong>Pain Relief at 2 hours</strong><sup>a</sup></p></td></tr><tr><td style="vertical-align:top"><p>N</p></td><td style="vertical-align:top"><p>498</p></td><td style="vertical-align:top"><p>503</p></td><td style="vertical-align:top"><p>515</p></td><td style="vertical-align:top"><p>544</p></td><td style="vertical-align:top"><p>523</p></td><td style="vertical-align:top"><p>521</p></td><td style="vertical-align:top"><p>534</p></td></tr><tr><td style="vertical-align:top"><p>% Responders</p></td><td style="vertical-align:top"><p>54.0</p></td><td style="vertical-align:top"><p>55.3</p></td><td style="vertical-align:top"><p>40.0</p></td><td style="vertical-align:top"><p>55.9</p></td><td style="vertical-align:top"><p>61.4</p></td><td style="vertical-align:top"><p>61.0</p></td><td style="vertical-align:top"><p>45.1</p></td></tr><tr><td style="vertical-align:top"><p>Difference from placebo (%)</p></td><td style="vertical-align:top"><p>14.0</p></td><td style="vertical-align:top"><p>15.3</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>10.8</p></td><td style="vertical-align:top"><p>16.3</p></td><td style="vertical-align:top"><p>15.9</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr></tbody></table><p dir="ltr"><sup>a</sup>&nbsp;&nbsp;&nbsp; The analysis of pain relief was descriptive and was not controlled for Type I error.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Figure 1 presents the percentage of patients achieving migraine pain freedom within 2&nbsp;hours following treatment in Studies 1 and 2.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Figure 1: Percentage of Patients Achieving Migraine Pain Freedom within 2 Hours in Pooled Studies 1 and 2</p><p dir="ltr"><!--[if gte vml 1]><v:shapetype
 id="_x0000_t75" coordsize="21600,21600" o:spt="75" o:preferrelative="t"
 path="m@4@5l@4@11@9@11@9@5xe" filled="f" stroked="f">
 <v:stroke joinstyle="miter"/>
 <v:formulas>
  <v:f eqn="if lineDrawn pixelLineWidth 0"/>
  <v:f eqn="sum @0 1 0"/>
  <v:f eqn="sum 0 0 @1"/>
  <v:f eqn="prod @2 1 2"/>
  <v:f eqn="prod @3 21600 pixelWidth"/>
  <v:f eqn="prod @3 21600 pixelHeight"/>
  <v:f eqn="sum @0 0 1"/>
  <v:f eqn="prod @6 1 2"/>
  <v:f eqn="prod @7 21600 pixelWidth"/>
  <v:f eqn="sum @8 21600 0"/>
  <v:f eqn="prod @7 21600 pixelHeight"/>
  <v:f eqn="sum @10 21600 0"/>
 </v:formulas>
 <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
 <o:lock v:ext="edit" aspectratio="t"/>
</v:shapetype><v:shape id="Picture_x0020_1" o:spid="_x0000_i1026" type="#_x0000_t75"
 style='width:540pt;height:380.25pt;visibility:visible;mso-wrap-style:square'>
 <v:imagedata src="file:///C:/Users/C284747/AppData/Local/Temp/msohtmlclip1/01/clip_image001.jpg"
  o:title="label_PF_Endcycle_obs2"/>
</v:shape><![endif]--><img width="720" height="507" alt="" src="file:///C:/Users/C284747/AppData/Local/Temp/msohtmlclip1/01/clip_image002.jpg" /></p><p dir="ltr"><sup>a</sup>&nbsp;&nbsp;&nbsp; The 50&nbsp;mg arm was only included in Study 2.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Figure 2 presents the percentage of patients achieving MBS freedom within 2&nbsp;hours in Studies 1 and 2.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Figure 2: Percentage of Patients Achieving MBS Freedom within 2 Hours in Pooled Studies 1 and 2</p><p dir="ltr"><!--[if gte vml 1]><v:shape id="Picture_x0020_2"
 o:spid="_x0000_i1025" type="#_x0000_t75" style='width:540pt;height:383.25pt;
 visibility:visible;mso-wrap-style:square'>
 <v:imagedata src="file:///C:/Users/C284747/AppData/Local/Temp/msohtmlclip1/01/clip_image003.jpg"
  o:title="label_MBS_Endcycle_obs2"/>
</v:shape><![endif]--><img width="720" height="511" alt="" src="file:///C:/Users/C284747/AppData/Local/Temp/msohtmlclip1/01/clip_image004.jpg" /></p><p dir="ltr"><sup>a</sup>&nbsp;&nbsp;&nbsp; The 50&nbsp;mg arm was only included in Study 2.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><em>Effects on Driving</em></p><p dir="ltr">Driving performance was assessed at 90&nbsp;minutes after administration of REYVOW 50&nbsp;mg, 100&nbsp;mg, 200&nbsp;mg, alprazolam 1&nbsp;mg, and placebo in a randomized, double-blind, placebo- and active-controlled, five-period crossover study in 90 healthy volunteers (mean age 34.9&nbsp;years) using a computer-based driving simulation. Driving performance was evaluated using a validated threshold established in a population with blood alcohol concentration of 0.05%. The primary outcome measure was the difference from placebo in the Standard Deviation of Lateral Position (SDLP), a measure of driving performance. A dose-dependent impairment of computer-based simulated driving performance was seen with all doses of REYVOW at 90&nbsp;minutes after administration.</p><p dir="ltr">Driving performance was also assessed at 8, 12, and 24&nbsp;hours after administration of REYVOW 100&nbsp;mg or 200&nbsp;mg, in a separate randomized, double-blind, placebo- and active-controlled, four-period crossover study in 67 healthy volunteers (mean age 32.8&nbsp;years) evaluating computer-based simulated driving performance using SDLP as the primary endpoint. Diphenhydramine 50&nbsp;mg was used as a positive control. The mean SDLP did not reach the threshold for driving impairment at 8&nbsp;hours or later after administration of REYVOW 100 or 200&nbsp;mg.</p><p dir="ltr"><strong>&nbsp;</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">Absorption</p><p dir="ltr">Following oral administration, lasmiditan is rapidly absorbed with a median t<sub>max</sub> of 1.8&nbsp;hours. In patients with migraine, the absorption or pharmacokinetics of lasmiditan was not different during a migraine attack versus during the interictal period.</p><p dir="ltr"><u>Effect of Food</u></p><p dir="ltr">Coadministration of lasmiditan with a high-fat meal increased the mean lasmiditan C<sub>max</sub> and AUC values by 22% and 19%, respectively, and delayed the median t<sub>max</sub> by 1 hour. This difference in exposure is not expected to be clinically significant <em>[see Posology and method of administration (4.2)]. </em>Lasmiditan was administered without regard to food in clinical efficacy studies.</p><p dir="ltr">Distribution</p><p dir="ltr">The human plasma protein binding of lasmiditan is approximately 55% to 60% and independent of concentration between 15 and 500&nbsp;ng/mL.</p><p dir="ltr">Elimination</p><p dir="ltr">Lasmiditan was eliminated with a geometric mean t<sub>&frac12;</sub> value of approximately 5.7&nbsp;hours. No accumulation of lasmiditan was observed with daily dosing. Lasmiditan is primarily eliminated via metabolism, with ketone reduction representing the major pathway. Renal excretion is a minor route of lasmiditan clearance.</p><p dir="ltr">Metabolism</p><p dir="ltr">Lasmiditan undergoes hepatic and extrahepatic metabolism primarily by non-CYP enzymes. The following enzymes are not involved in metabolism of lasmiditan: MAO-A, MAO-B, flavin monooxygenase 3, CYP450 reductase, xanthine oxidase, alcohol dehydrogenase, aldehyde dehydrogenase, and aldo-keto reductases. Lasmiditan is also metabolized to M7 (oxidation on piperidine ring) and M18 (combination of M7 and M8 pathways). These metabolites are considered pharmacologically inactive.</p><p dir="ltr">Excretion</p><p dir="ltr">Recovery of unchanged lasmiditan in urine was low and accounted for approximately 3% of the dose. Metabolite S-M8 represented approximately 66% of the dose in urine, with the majority of recovery within 48 hours postdose.</p><p dir="ltr">Specific Populations</p><p dir="ltr">Age, Sex, Race/Ethnicity, and Body Weight</p><p dir="ltr">Based on a population pharmacokinetic (PK) analysis, age, sex, race/ethnicity, and body weight did not have a significant effect on the PK (C<sub>max</sub> and AUC) of lasmiditan. Therefore, no dose adjustments are warranted based on age, sex, race/ethnicity, or body weight.</p><p dir="ltr">Geriatric Use</p><p dir="ltr">In a clinical pharmacology study, administration of lasmiditan to subjects 65&nbsp;years of age or older demonstrated 26% greater exposure in AUC(0‑&yen;) and 21% higher C<sub>max</sub>, compared to subjects 45&nbsp;years of age or less. This difference in exposure is not expected to be clinically significant <em>[see Use in Specific Populations (4.2)]</em>.</p><p dir="ltr">Renal Impairment</p><p dir="ltr">In a clinical pharmacology study, administration of lasmiditan to subjects with severe renal impairment (eGFR &lt;30&nbsp;mL/min/1.73&nbsp;m<sup>2</sup>) demonstrated 18% greater exposure in AUC(0‑&yen;) and 13% higher C<sub>max</sub>, compared to subjects with normal renal function. No dose adjustment is required based on renal function.</p><p dir="ltr">Hepatic Impairment</p><p dir="ltr">In a clinical pharmacology study, subjects with mild and moderate hepatic impairment (Child-Pugh Class A and B, respectively) demonstrated 11% and 35%, respectively, greater exposure [AUC(0‑&yen;)] to lasmiditan, compared to subjects with normal hepatic function. The C<sub>max</sub> were higher by 19% and 33%, respectively, for subjects with mild and moderate hepatic impairment. This difference in exposure is not expected to be clinically significant. The use of lasmiditan has not been studied in subjects with severe hepatic impairment <em>[see Use in Specific Populations (4.2)]</em>.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Drug Interaction Studies</p><p dir="ltr">Potential for Lasmiditan to Affect Other Drugs</p><p dir="ltr"><em>Drug Metabolizing Enzymes</em></p><p dir="ltr">Lasmiditan is an <em>in-vitro</em> inhibitor of CYP2D6 but did not significantly inhibit the activity of other CYP450 enzymes. Modeling and simulation of the impact of lasmiditan on the exposure of dextromethorphan, a recognized sensitive CYP2D6 substrate, indicate that lasmiditan is unlikely to exert clinically significant inhibition of CYP2D6. Lasmiditan, M7, S-M8, and [S,R]-M18 are not reversible or time-dependent inhibitors of monoamine oxidase A (MAO-A).</p><p dir="ltr">Daily dosing of lasmiditan did not alter the PK of midazolam, caffeine, or tolbutamide, which are substrates of CYP3A, CYP1A2, and CYP2C9, respectively. Coadministration of lasmiditan with sumatriptan, propranolol, or topiramate resulted in no clinically meaningful changes in exposure of these medicinal products.</p><p dir="ltr"><em>Drug Transporters</em></p><p>In a drug interaction study in healthy volunteers, co-administration of 200 mg REYVOW with dabigatran (P-gp substrate) increased the systemic exposures, AUC and C<sub>max</sub>, of dabigatran by 25% and 22%, respectively <em>[see Interaction with other medicinal products and other forms of interaction (4.5)]. </em>Co-administration of 200 mg REYVOW with rosuvastatin (BCRP substrate) did not affect exposures of rosuvastatin.</p><p dir="ltr">Lasmiditan inhibits OCT1 <em>in-vitro</em>. However, in a drug-drug interaction study with lasmiditan and sumatriptan (OCT1 substrate), no change in sumatriptan PK was observed. Lasmiditan inhibits renal efflux transporters, MATE1 and MATE2-K, <em>in-vitro</em>.</p><p dir="ltr">Potential for Other Drugs to Affect Lasmiditan</p><p dir="ltr"><em>Drug Metabolizing Enzymes</em></p><p dir="ltr">Lasmiditan undergoes hepatic and extrahepatic metabolism primarily by non-CYP enzymes. Therefore, it is unlikely that CYP inhibitors or inducers will affect lasmiditan pharmacokinetics. Clinical studies of lasmiditan with sumatriptan, propranolol, or topiramate did not show any significant drug interaction potential.</p><p dir="ltr"><em>Drug Transporters</em></p><p dir="ltr">Lasmiditan is a substrate for P-gp <em>in-vitro</em>.</p><p dir="ltr"><strong>&nbsp;</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr"><u>Carcinogenesis, Mutagenesis, Impairment of Fertility</u></p><p dir="ltr"><em>Carcinogenesis</em></p><p dir="ltr">No drug-related tumors were observed following oral administration of lasmiditan to TgRasH2 mice at doses of up to 150 (males) or 250 (females) mg/kg/day for 26 weeks or to rats at doses of up to 75&nbsp;mg/kg/day for 2&nbsp;years. Plasma exposures (AUC) at the highest dose tested in rats were approximately 15 times that in humans at the maximum recommended human dose (MRHD) of 200&nbsp;mg/day.</p><p dir="ltr"><em>Mutagenesis</em></p><p dir="ltr">Lasmiditan was negative in in vitro (bacterial reverse mutation, chromosomal aberration in mammalian cells) and in vivo (mouse bone marrow micronucleus) assays.</p><p dir="ltr"><em>Impairment of Fertility</em></p><p dir="ltr">Oral administration of lasmiditan to male (0, 100, 175, or 200&nbsp;mg/kg/day) or female (0, 100, 150, or 200&nbsp;mg/kg/day) rats prior to and during mating and continuing in females to Gestation Day 7 resulted in no adverse effects on fertility or reproductive performance. Plasma exposures (AUC) at the highest dose tested (200&nbsp;mg/kg/day) were approximately 26 times that in humans at the MRHD.</p><p dir="ltr">&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; croscarmellose sodium [E468]</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; magnesium stearate [E572]</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; microcrystalline cellulose [460(i)] or cellulose, microcrystalline</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; sodium lauryl sulfate [E487] or sodium lauril sulfate</p><p dir="ltr">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; pregelatinized starch or starch pregelatinized</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">Not applicable.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                3 years 
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">Store below 30&deg;C.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">REYVOW (lasmiditan) 50&nbsp;mg tablets are light gray, oval, film coated, tablets with &ldquo;L-50&rdquo; debossed on one side and &ldquo;4312&rdquo; on the other.</p><p dir="ltr">REYVOW (lasmiditan) 100&nbsp;mg tablets are light purple, oval, film coated, tablets with &ldquo;L-100&rdquo; debossed on one side and &ldquo;4491&rdquo; on the other.</p><p dir="ltr">REYVOW is available in packs containing 4, 8 and 12 tablets.</p><p dir="ltr">&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" dir="ltr"><tbody><tr><td rowspan="2" style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p><strong>Strengths</strong></p></td></tr><tr><td style="vertical-align:top"><p>50&nbsp;mg</p></td><td style="vertical-align:top"><p>100&nbsp;mg</p></td></tr><tr><td style="vertical-align:top"><p><strong>Tablet color</strong></p></td><td style="vertical-align:top"><p>Light gray</p></td><td style="vertical-align:top"><p>Light purple</p></td></tr><tr><td style="vertical-align:top"><p><strong>Imprint (debossed)</strong></p></td><td style="vertical-align:top"><p>L-50<br />4312</p></td><td style="vertical-align:top"><p>L-100<br />4491</p></td></tr></tbody></table><p dir="ltr">&nbsp;</p><p dir="ltr">Not all strengths and pack sizes may be marketed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">No special requirements for disposal.</p><p>&nbsp;</p><p dir="ltr">Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana (IN) 46285 USA
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                15 September 2022
Version 3
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>